TORRENT PHARMACEUTICALS
Quarterly Results Analysis [Sep2024]
TORRENT PHARMACEUTICALS Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,889 Cr | ₹2,859 Cr | ₹2,745 Cr | ₹2,732 Cr | ₹2,660 Cr | ₹2,591 Cr | ₹2,491 Cr | ₹2,491 Cr |
Expenses | ₹1,950 Cr | ₹1,955 Cr | ₹1,862 Cr | ₹1,863 Cr | ₹1,835 Cr | ₹1,800 Cr | ₹1,764 Cr | ₹1,767 Cr |
Operating Income | ₹939 Cr | ₹904 Cr | ₹883 Cr | ₹869 Cr | ₹825 Cr | ₹791 Cr | ₹727 Cr | ₹724 Cr |
Other Income | ₹-16 Cr | ₹24 Cr | ₹31 Cr | ₹-33 Cr | ₹26 Cr | ₹34 Cr | ₹9 Cr | ₹-10 Cr |
Interest | ₹64 Cr | ₹75 Cr | ₹80 Cr | ₹80 Cr | ₹91 Cr | ₹103 Cr | ₹107 Cr | ₹102 Cr |
Depreciation | ₹198 Cr | ₹197 Cr | ₹203 Cr | ₹213 Cr | ₹201 Cr | ₹191 Cr | ₹196 Cr | ₹193 Cr |
Profit Before Tax | ₹661 Cr | ₹656 Cr | ₹631 Cr | ₹631 Cr | ₹559 Cr | ₹531 Cr | ₹433 Cr | ₹419 Cr |
Profit After Tax | ₹453 Cr | ₹457 Cr | ₹449 Cr | ₹443 Cr | ₹386 Cr | ₹378 Cr | ₹287 Cr | ₹292 Cr |
EPS | ₹13.38 | ₹13.50 | ₹13.27 | ₹13.09 | ₹11.40 | ₹11.17 | ₹8.48 | ₹8.63 |
Industry Peers & Returns | 1W | 1M | 1Y |
TORRENT PHARMACEUTICALS | -1.8% | -10.2% | 51.3% |
SUN PHARMACEUTICAL INDUSTRIES | -1.4% | -7.1% | 48% |
CIPLA | -3.5% | -5.2% | 18% |
DR REDDYS LABORATORIES | -3.9% | -10.1% | 10.1% |
ZYDUS LIFESCIENCES | -0.3% | -7.3% | 52.2% |
DIVIS LABORATORIES | 1.5% | -2.1% | 63% |
MANKIND PHARMA | -2.3% | -3% | 39.6% |
LUPIN | -2.4% | -6.4% | 73.9% |
AUROBINDO PHARMA | -1.5% | -15.2% | 27.9% |
TORRENT PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 1.05 % |
Y-o-Y | 8.61 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹2,889 Cr | 1.05 | |
Jun2024 | ₹2,859 Cr | 4.15 | |
Mar2024 | ₹2,745 Cr | 0.48 | |
Dec2023 | ₹2,732 Cr | 2.71 | |
Sep2023 | ₹2,660 Cr | 2.66 | |
Jun2023 | ₹2,591 Cr | 4.01 | |
Mar2023 | ₹2,491 Cr | 0.00 | |
Dec2022 | ₹2,491 Cr | - |
TORRENT PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 3.87 % |
Y-o-Y | 13.82 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹939 Cr | 3.87 | |
Jun2024 | ₹904 Cr | 2.38 | |
Mar2024 | ₹883 Cr | 1.61 | |
Dec2023 | ₹869 Cr | 5.33 | |
Sep2023 | ₹825 Cr | 4.30 | |
Jun2023 | ₹791 Cr | 8.80 | |
Mar2023 | ₹727 Cr | 0.41 | |
Dec2022 | ₹724 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 2.78 % |
Y-o-Y | 4.77 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 32.5% | 2.78 | |
Jun2024 | 31.62% | -1.71 | |
Mar2024 | 32.17% | 1.13 | |
Dec2023 | 31.81% | 2.55 | |
Sep2023 | 31.02% | 1.60 | |
Jun2023 | 30.53% | 4.59 | |
Mar2023 | 29.19% | 0.45 | |
Dec2022 | 29.06% | - |
TORRENT PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -0.88 % |
Y-o-Y | 17.36 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹453 Cr | -0.88 | |
Jun2024 | ₹457 Cr | 1.78 | |
Mar2024 | ₹449 Cr | 1.35 | |
Dec2023 | ₹443 Cr | 14.77 | |
Sep2023 | ₹386 Cr | 2.12 | |
Jun2023 | ₹378 Cr | 31.71 | |
Mar2023 | ₹287 Cr | -1.71 | |
Dec2022 | ₹292 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -1.88 % |
Y-o-Y | 8.06 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 15.68 % | -1.88 | |
Jun2024 | 15.98 % | -2.32 | |
Mar2024 | 16.36 % | 0.86 | |
Dec2023 | 16.22 % | 11.78 | |
Sep2023 | 14.51 % | -0.55 | |
Jun2023 | 14.59 % | 26.65 | |
Mar2023 | 11.52 % | -1.71 | |
Dec2022 | 11.72 % | - |
TORRENT PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -0.89 % |
Y-o-Y | 17.37 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹13.38 | -0.89 | |
Jun2024 | ₹13.5 | 1.73 | |
Mar2024 | ₹13.27 | 1.38 | |
Dec2023 | ₹13.09 | 14.82 | |
Sep2023 | ₹11.4 | 2.06 | |
Jun2023 | ₹11.17 | 31.72 | |
Mar2023 | ₹8.48 | -1.74 | |
Dec2022 | ₹8.63 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD